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The human immunodeficiency virus type 1 (HIV-1) Tat protein activates transcription elongation by stim-
ulating the Tat-activated kinase (TAK/p-TEFb), a protein kinase composed of CDK9 and its cyclin partner,
cyclin T1. CDK9 is able to hyperphosphorylate the carboxyl-terminal domain (CTD) of the large subunit of
RNA polymerase during elongation. In addition to TAK, the transcription elongation factor Spt5 is required
for the efficient activation of transcriptional elongation by Tat. To study the role of Spt5 in HIV transcription
in more detail, we have developed a three-stage Tat-dependent transcription assay that permits the isolation
of active preinitiation complexes, early-stage elongation complexes, and Tat-activated elongation complexes.
Spt5 is recruited in the transcription complex shortly after initiation. After recruitment of Tat during elon-
gation through the transactivation response element RNA, CDK9 is activated and induces hyperphosphory-
lation of Spt5 in parallel to the hyperphosphorylation of the CTD of RNA polymerase II. However, immu-
nodepletion experiments demonstrate that Spt5 is not required for Tat-dependent activation of the kinase.
Chase experiments using the Spt5-depleted extracts demonstrate that Spt5 is not required for early elongation.
However, Spt5 plays an important role in late elongation by preventing the premature dissociation of RNA
from the transcription complex at terminator sequences and reducing the amount of polymerase pausing at
arrest sites, including bent DNA sequences. This novel biochemical function of Spt5 is analogous to the
function of NusG, an elongation factor found in Escherichia coli that enhances RNA polymerase stability on
templates and shows sequence similarity to Spt5.
Transcription from the human immunodeficiency virus
(HIV) promoter is regulated both at the level of initiation and
elongation (for recent reviews, see references 14, 26, 48, and
54). In activated T cells and other permissive cell types, initi-
ation of HIV transcription is very efficient, but production of
full-length transcripts requires the viral regulatory protein Tat.
In the absence of Tat, the majority of RNA polymerase II
complexes that initiate transcription at the HIV promoter dis-
engage from the template near to the promoter (24, 35). Tat
strongly activates RNA polymerase processivity and permits
the synthesis of full-length HIV transcripts both in vivo and in
cell-free transcription systems (11, 17, 27, 28, 39, 40, 50, 53).
Tat is an RNA-binding protein that is recruited to early HIV
transcription complexes by binding to the transactivation re-
sponse element (TAR), an RNA stem-loop structure that is
located at the 5 end of HIV transcripts (5, 12, 28, 51, 52). The
interaction between Tat and TAR involves not only the bind-
ing of Tat to TAR RNA but also its association with the
Tat-activated kinase (TAK) (20, 38, 69), a protein kinase that
is able to phosphorylate the carboxyl-terminal domain (CTD)
of the large subunit of RNA polymerase II (21, 43, 65).
TAK is composed of a kinase subunit, CDK9, and its cyclin
partner, cyclin T1 (CycT1) (38, 60, 69). In addition to regulat-
ing CDK9, CycT1 is able to increase the affinity of Tat for TAR
RNA (60). In the absence of CycT1, the recognition sequence
of Tat on TAR is restricted to the region surrounding a trinu-
cleotide bulge located near the apex of the TAR RNA stem-
loop structure. In the presence of CycT1, the recognition se-
quence on TAR RNA is extended to include the apical loop
sequence (16, 60).
Formation of the quaternary complex between CDK9,
CycT1, Tat, and TAR RNA induces conformational changes in
the enzyme complex that result in the constitutive activation of
the CDK9 kinase (6, 8, 13, 16, 23, 34). The CDK9 kinase is
then able to hyperphosphorylate the CTD of the RNA poly-
merase, resulting in the formation of a novel and unusually
highly phosphorylated form of the polymerase which we have
called RNA polymerase IIo* (21). Although experimental ev-
idence demonstrating that RNA polymerase processivity is
regulated by CTD phosphorylation has not yet been presented,
it seems likely that CTD modification has a direct influence on
elongation.
Modification of the transcription complex by Tat and TAK
to make it more processive also requires specific cofactors that
have been identified using partially reconstituted cell-free tran-
scription systems (61, 67, 68). One of the best characterized of
these factors is Spt5, a subunit of the 5,6-dichloro-1--D-ribo-
furanosylbenzimidazole (DRB) sensitivity-inducing factor
(DSIF). In normal transcription, DSIF works in concert with
the negative elongation factor (NELF) to induce polymerase
pausing near promoter start sites (57–59, 62, 63). This pausing
event can be enhanced by DRB and reversed by a CDK9-
dependent phosphorylation event. In addition to playing a role
in early transcription, Spt5 may act as a generalized elongation
factor. In an important experiment demonstrating a direct role
for Spt5 in HIV transcription, Gaynor and coworkers (22, 61)
showed that immunodepletion of Spt5 from transcription ex-
tracts strongly inhibited Tat-activated transcription but had
only minimal effects on basal transcription. A further link be-
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tween Tat and Spt5 comes from very recent studies demon-
strating that Spt5 can be phosphorylated by CDK9 (22, 31, 47).
Although the evidence that Spt5 is needed as a Tat cofactor
is compelling, one limitation of the published studies is that
they did not distinguish between the possibilities that Spt5 and
CDK9 might play distinct biochemical roles in promoting the
stability and/or processivity of Tat-activated transcription com-
plexes or, alternatively, whether Spt5 is required for the acti-
vation or regulation of CDK9. To examine the roles of Spt5,
CDK9, and Tat in HIV transcription in greater detail, we used
an immobilized DNA template assay (21, 28) to isolate tran-
scription complexes paused during three distinct phases of the
transcription cycle. The results demonstrate that Spt5 plays a
distinct role in transcription elongation by promoting the sta-
bility of transcription complexes at terminator sequences. This
biochemical function is analogous to the role of the Escherichia
coli RNA polymerase-binding protein NusG, a prokaryotic
elongation factor that is able to stabilize prokaryotic RNA
polymerase during elongation (18, 45).
MATERIALS AND METHODS
Template DNAs. The templates contain the entire HIV long terminal repeat
(LTR) from HIVNL-4-3 (1). PW1 carries the wild-type (wt) TAR region. Muta-
tions in the Tat-binding site (G26·C39 to C·G; mGC) or in the loop (G32–34 to
UUU; mLG) were described previously (11). pH3.3, which contains two tandem
bent DNA arrest sequences (4, 30), was constructed by inserting the sequence
5-CTAGCATTTTTAAAAGAGGGACGTTTTTTTCCCTTTTTTGGAGAG
GCGGAAACTTGATGT-3 between the NheI and AccI sites flanking the stem-
loop terminator sequence of pW1. The control plasmid was created by replacing
the terminator sequence by a DNA sequence of equivalent length from the
corresponding region of the HIV genome (5-GAGCGTCGGTATTAAGCGG
GGGAGAATTAGATAAGT-3).
Biotinylation of DNA and binding to streptavidin beads. After cleavage with
XbaI, template DNAs were 5 and 3 end labeled with biotin-16-dUTP (Roche)
using Klenow enzyme (Roche). The free biotin-dUTP was removed from the
biotinylated DNA by gel filtration using Sephadex G-50 (Pharmacia). Biotin-
DNA was absorbed onto 50 l of streptavidin magnetic beads (Dynabeads M280
streptavidin; Dynal). The beads were prewashed in EBCD wash buffer (50 mM
Tris-HCl [pH 8.0], 120 mM NaCl, 0.5% NP-40, 5 mM dithiothreitol [DTT], 4
mM MgCl2). DNA was incubated on ice for 5 min before being washed in EBCD
to remove unbound DNA. The final amount of DNA bound on the beads was 0.5
g.
Cell-free full transcription reactions. Streptavidin-bound DNA was incubated
in a 40-l reaction containing final concentrations (including the nuclear extract)
of 20 mM HEPES (pH 7.9), 3 mM DTT, 11.25 M ZnSO4, 4 mM MgCl2, 75 mM
KCl, 50 M ATP, 50 M CTP, 50 M GTP, 5 M UTP, 2.5 g of creatine kinase
per ml, 10 M creatine phosphate, and 1 g of poly(dI-dC) (Roche), in the
presence of 20 l of HeLa nuclear extract and 5 to 10 Ci of [-32P]UTP.
Recombinant Tat (20 ng) and Lac repressor protein (100 ng) were added where
indicated. The reaction mixtures were incubated for 20 min at 30°C and then
washed twice with 250 l of EBCD buffer containing 0.1% Sarkosyl. The immo-
bilized templates were separated by magnetic concentration before being resus-
pended in 50 l of 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA. The bound and
free fractions collected after magnetic separation were treated by the same
procedure, and equivalent amounts of the two fractions were analyzed.
To analyze RNA transcripts, 50 l of stop buffer (300 mM sodium acetate, 1%
SDS, 20 mM EDTA, 0.1 g of tRNA per l) was added to each sample and the
samples were subjected to phenol extraction and ethanol precipitation. The
precipitated nucleic acids were dissolved in 10 l of RNA loading buffer (80%
[vol/vol] formamide, 10 mM Tris-HCl [pH 8.0], 0.1 mM EDTA, 0.1% bromo-
phenol blue, 0.1% xylene cyanol), denatured at 95°C for 5 min, and analyzed by
electrophoresis on a 6% polyacrylamide gel containing 7 M urea and TBE buffer
(90 mM Tris base, 89 mM boric acid, 2.5 mM EDTA).
To analyze the protein constituents of the transcription complexes, washed
beads were mixed with sodium dodecyl sulfate (SDS) loading buffer (50 mM
Tris-HCl [pH 6.8], 2.5% SDS, 100 mM -mercaptoethanol, 10% glycerol, 0.02%
bromophenol blue), heated to 95°C for 5 min, and loaded onto appropriate
precast protein gels (Novex/Invitrogen).
Three-stage transcription reactions. For the three-stage transcription assays,
the HeLa nuclear extract was first treated with 20 U of hexokinase (HK) per ml
and 25 mM glucose for 5 min at 30°C to remove endogenous ATP. Preinitiation
complexes (PIC) were prepared by incubating 0.5 g of bound DNA for 10 min
at 30°C in 40-l reaction mixtures containing 20 mM HEPES (pH 7.9), 3 mM
DTT, 11.25 M ZnSO4, 4 mM MgCl2, 50 mM KCl, 1 g of poly(dI-dC), and 20
l of HK- and glucose-treated HeLa nuclear extract. To permit transcription
initiation in the absence of ATP, 50 M dATP was added as a substitute
phosphate donor.
After formation of the preinitiation complexes, early transcription complexes
paused at the uridine residue at 14 were prepared by adding 10 Ci of
[-32P]UTP, 50 M CTP, 50 M GTP, 2.5 g of creatine kinase per ml, and 10
M creatine phosphate to the PIC reaction mixtures and incubating them for a
further 10 min at 30°C. Under these labeling conditions, we routinely observed
paused polymerases between 1 and 14 which arose due to the low levels of
UTP. To circumvent this problem, we followed the initial reaction by a 2-min
incubation in the presence of 125 M UTP. At the end of the elongation
reaction, the beads carrying complexes at 14 were washed once with 250 l of
EBCD buffer.
For elongation from 14 to the end of the template, the beads were resus-
pended in 40 l of buffer containing 20 mM HEPES (pH 7.9), 3 mM DTT,
11.25M ZnSO4, 4 mM MgCl2, 100 mM KCl, 2.5 g of creatine kinase per ml,
10 M creatine phosphate, 5 M UTP, and 50 M each ATP, CTP, and GTP in
the absence or presence of 10 l of fresh nuclear extract and incubated for 15
min at 30°C. Where indicated, Tat (20 ng) was added during this chase.
Aliquots corresponding to one-fifth of the reaction mixture were removed
following each step (PIC, 14, or elongation) for analysis of RNA and protein.
The beads were washed twice with EBCD buffer, and RNA and protein analysis
was carried out as described above.
Preparation of recombinant p65 protein. A recombinant baculovirus express-
ing polyhistidine-tagged p65 was provided by J Hiscott (36). A 350-ml volume of
Sf9 cells (1.2  106/ml) was infected at a final concentration of 1% first-passage
virus and incubated for 3 days at 27°C. The cell pellet was resuspended in 10 ml
of homogenization buffer (10 mM Tris-HCl [pH 7.5], 500 mM NaCl, 0.1%
NP-40, 15 mM imidazole, 2 mM 2-mercaptoethanol, 2 mM phenylmethylsulfonyl
fluoride [PMSF], 10% glycerol, complete protease inhibitor cocktail [Boehring-
er-Mannheim]), and the cells were then lysed using a Dounce homogenizer (A
pestle). After centrifugation at 15,000 rpm in an SS-34 rotor for 10 min, the
cleared cell lysate was applied to a Quick 300 Ni-nitrilotriacetic acid syringe
column (Novagen). The column was washed twice with wash buffer (10 mM
Tris-HCl [pH 7.5], 200 mM NaCl, 0.2% NP-40, 15 mM imidazole, 2 mM 2-mer-
captoethanol, 2 mM PMSF, 10% glycerol), and the recombinant protein was
then eluted with 1 ml of elution buffer (10 mM Tris-HCl [pH 7.5], 100 mM NaCl,
0.1% NP-40, 250 mM imidazole, 2 mM 2-mercaptoethanol, 2 mM PMSF, 10%
glycerol). The eluted protein was then dialyzed against NDBZ buffer (20 mM
HEPES [pH 7.9], 100 mM KCl, 2 mM MgCl2, 10M ZnSO4, 10% glycerol, 2 mM
DTT) and stored in liquid nitrogen.
Dephosphorylation of elongation complexes. Elongation complexes bound on
magnetic beads were obtained as described in the previous section and purified
by washing the beads twice with EBCD buffer containing 0.1% Sarkosyl. Com-
plexes were resuspended in 10 mM HEPES (pH 7.9), 2 mM DTT, 6.25 M
ZnSO4, and 4 mM MgCl2 and incubated with 2.5 U of protein phosphatase 1 for
1 h at 30°C, with frequent mixing.
Antibodies and Western blot analysis. Protein samples were loaded onto
Novex precast gels. For the RNA polymerase II and Spt5 analysis, we used 3 to
8% Tris-acetate gels. For the other proteins, we used either 10 or 4 to 12%
Bis-Tris gels. After SDS-polyacrylamide gel electrophoresis, proteins were trans-
ferred to nitrocellulose membranes (Schleicher & Schuell) and probed with
appropriate antibodies. Spt5 was detected using either a polyclonal antibody
directed against the terminal 852 to 1,087 amino acids of the protein (kindly
supplied by R. Gaynor) or a monoclonal antibody directed against amino acids
866 to 985 (anti-DSIF-p160; BD Transduction Laboratories). The LacR mono-
clonal antibody (NL1.1B2.10) has been described previously (28, 29). Finally, the
following polyclonal antibodies were supplied by Santa Cruz Biotechnology:
RNA polymerase II (N-20), CDK9 (H-169), cyclin T1 (C-20), CDK7 (C-19),
cyclin H (D-10), TAFII250 (6B3), and RAP74 (N-16).
Immunodepletion of nuclear extracts. Protein A-Sepharose beads were
washed twice with phosphate-buffered saline (PBS) (125 mM NaCl, 10 mM
Na2PO4 [pH 7.0]), saturated with bovine serum albumin for 30 min, and then
washed twice again with PBS before being incubated with antibodies for 1 h at
4°C with rolling mixing. Between 20 and 40 g of antibodies was bound to 100 l
of beads. The antibodies used were polyclonal anti-CDK7 (30 g of C-19), a
mixture of equal amounts of polyclonal anti-CDK9 (20 g of H-169) and affinity-
1080 BOURGEOIS ET AL. MOL. CELL. BIOL.
 o
n








purified polyclonal anti-CycT1 (20 g), monoclonal anti-DSIF-p160 (20 g) or
control rabbit immunoglobulin G (20 g to 40 g [Santa Cruz Biotechnology]).
For Spt5 and TAK codepletion, 20 g of each antibody (Spt5, CDK9, and
CycT1) was used per 100 l of beads. The beads were washed twice with PBS
buffer to remove the free antibodies.
To deplete 100 l of nuclear extract, four sequential depletions using 25 l of
antibody bound to beads were performed. The initial depletion mixture was
incubated for 2 h, and the subsequent depletions were incubated for 1 h each.
After the final round of depletion, the nuclear extract was collected and incu-
bated for 20 min with 10 to 20 l of bovine serum albumin-saturated protein
A-Sepharose beads to remove remaining free antibodies from the extract. Beads
were collected by centrifugation, and the nuclear extract was used immediately in
the transcription assays or frozen in liquid nitrogen. The efficiency and specificity
of the depletions were checked by analysis of the nuclear extract by Western
blotting with various antibodies.
RESULTS
Experimental design. In the experiments described below,
we employed a three-stage transcription system that permits
the sequential analysis of preinitiation complexes, complexes
paused during early elongation, and complexes paused after
elongation through TAR (Fig. 1). This experimental system is
based on our previous studies using immobilized DNA tem-
plates to purify preinitiation and elongation transcription com-
plexes in vitro and to analyze their functional characteristics
(21, 28).
In the first stage of the reaction, preinitiation complexes that
contained only nonphosphorylated RNA polymerase II were
assembled using nuclear extracts that were depleted of ATP by
treatment with hexokinase and glucose (21). Phosphorylation
of the RNA polymerase II CTD was then initiated by adding
dATP. The second stage of the reaction creates transcription
complexes that are paused at 14, a stage that is shortly after
initiation but before complete clearance of the promoter.
These complexes were obtained by chasing the preinitiation
complexes in the presence of all the ribonucleotides except
ATP, using dATP as a phosphate donor for the phosphoryla-
tion of the RNA polymerase II CTD (44, 46, 47). Because
there is no ATP remaining in the extract, elongation stops at
14, immediately before the first adenine on the template,
which is at position 15 (Fig. 1). Addition of ATP to the
reaction mixture permits further elongation. Since no addi-
tional label is added during the chase, the only products de-
tected are the result of elongation of the arrested transcripts
and are not due to new initiation events (21, 28).
The majority of the template DNAs used in these experi-
ments carried a synthetic terminator sequence () placed be-
FIG. 1. Three-stage Tat-dependent transcription reactions.
(A) Immobilized template. The DNA template, containing the HIV
LTR and an artificial terminator (), was biotinylated on both ends
using Klenow DNA polymerase and bound to streptavidin-coated
magnetic beads. (B) PIC formation. PIC are obtained following incu-
bation of immobilized templates with a nuclear extract (NE) depleted
of ATP by a treatment with HK and glucose. Phosphorylation of the
CTD of RNA polymerase is allowed by adding dATP in the reaction
mixture. Protein composition of preinitiation complexes can be ana-
lyzed by Western blotting. (C) Pausing at 14. Early elongation com
plexes were formed by incubation of the preinitiation complexes in the
absence of ATP and in the presence of CTP, GTP, and [-32P]UTP.
This allows the RNA polymerase to carry out the transcription of the
first 14 nt of the RNA chain and to pause before the first A residue
located at 15 on the DNA template. (D) Chase. Elongation com-
plexes were obtained by allowing the 14 complexes to extend follow-
ing addition of all the nucleotides in the presence or absence of Tat.
The population of elongation complexes, which have reached various
points on the template, can be purified by washing the beads and
analyzed for their RNA and/or protein composition. Released tran-
scripts can be analyzed by purifying the RNA present in the superna-
tant collected after magnetic separation. The major stop sites corre-
spond to the end of TAR, the terminator (), and the end of the
template (	).
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tween 290 and 326, downstream of the start of transcrip-
tion. The terminator contains a stable RNA stem-loop
structure followed by a tract of 9 uridine residues (17, 50).
Transcription complexes reaching the terminator either disso-
ciate from the template at the end of the U tract or remain
bound to the template at the end of the stem-loop structure.
Alternatively, templates carried arrest sites created by bent
DNA sequences (4, 30). Synthesis of full-length transcripts
from these templates is greatly enhanced in the presence of Tat
and Spt5. To measure the effects of Spt5 on transcript release,
we also took advantage of the immobilized template system to
separate transcription complexes that remained tightly bound
to the template from the transcripts that had been released due
to termination activity.
Tat activation of transcription complexes paused during
early elongation. As shown in Fig. 2A, the staged transcription
reactions permit efficient chases from the early elongation
complexes arrested at 14 to late-stage elongation complexes.
The 14 transcripts were synthesized with equal efficiency in
the presence and absence of Tat (data not shown). All of the
complexes paused at 14 resume elongation following the
addition of a full complement of nucleotides. However, effi-
cient transcription elongation requires the addition of nuclear
extract during the chase. In the absence of added extract, the
majority of the transcription complexes disengage from the
template shortly after TAR (59) and short RNA transcripts
appear in the free fraction, suggesting that general elongation
factors present in the extract are required to read through
TAR. There is also significant release of transcripts at the end
of the second major stem-loop structure in the HIV leader
sequence (stem-loop II) at 104, and only a limited number of
transcription complexes reach the terminator ().
By contrast, in the presence of nuclear extract, the transcrip-
tion complexes are stabilized on the template and compara-
tively few transcripts dissociate from the template after TAR
and stem-loop II. However, a significant fraction of the tran-
scription complexes dissociate from the template at the artifi-
cial terminator sequence (). Efficient synthesis of the runoff
transcript (518 nt) is strongly dependent on the presence of the
Tat protein in the reaction (Fig. 2A). Therefore, the net effect
of Tat is to increase the proportion of transcripts that are able
to read through the terminator sequence and remain tightly
associated with the template.
The ability of Tat to promote readthrough of the terminator
sequence cannot be mimicked by general activators such as the
transcription factor NF-
B p65 (Fig. 2B). Addition of p65
stimulated basal transcription 2.7-fold but did not alter the
distribution of transcript lengths or the ability of Tat to further
stimulate elongation. For example, addition of Tat to the re-
action mixture in the absence of p65 resulted in a reduction of
short transcripts and a 16.9-fold increase in the amount of
runoff product. Similarly, in the presence of p65, Tat increased
the amount of runoff transcripts 10.3-fold.
Similar strategies for studying transcription complexes dur-
ing various stages of initiation and elongation have been em-
ployed by other groups studying HIV transcription (37, 44, 47,
65). However, in all of these studies the Tat response was lost
or severely inhibited. The experimental system that we devel-
oped is unique because we have been able to retain a Tat
response during a chase from complexes paused during early
elongation that is nearly equivalent to that observed in unin-
terrupted transcription reactions. In addition to its experimen-
tal utility, the system provides evidence that all the elongation
factors required for Tat activation are present at each stage in
the reaction.
Three technical features of the system deserve mention.
First, we have found that preinitiation complexes after phos-
phorylation by dATP are extremely fragile and that critical
factors that cannot be subsequently replaced are lost when
these complexes are washed with isotonic buffers. Second, in
the chase experiments that follow, Tat is added to complexes
that have reached 14. This demonstrates that Tat is fully
functional even when it is added after initiation, in agreement
with a previous report (37). Finally, it should be noted that
since no new label is introduced during the chase, the results
provide a direct comparison of transcription elongation in the
presence and absence of Tat. By contrast, under continuous
labeling conditions, the proportion of long transcripts is exag-
gerated because of their increased specific activity.
Spt5 prevents premature release of transcripts at termina-
tor sequences. We next examined the role of Spt5 during var-
ious stages of elongation. To selectively remove Spt5 from the
transcription system, without removing other transcription
elongation factors, nuclear extracts were immunodepleted us-
ing a mouse monoclonal antibody raised against Spt5. As a
control, nuclear extracts were also depleted using equivalent
amounts of rabbit immunoglobulin G (mock depleted).
The results of transcription experiments performed with the
mock-depleted and Spt5-depleted extracts are shown in Fig. 3.
In the mock-depleted extracts, addition of recombinant Tat
protein to the reaction stimulated the production of runoff
product (	) remaining bound to the template by more than
30-fold. Removal of Spt5 from the extracts by immunodeple-
tion reduced the amount of runoff product in the bound frac-
tion by sevenfold but did not reduce the amount of products
found at the terminator. Thus, Spt5 is required for maximal
readthrough of the terminator sequence.
Examination of transcripts released from the templates
shows that the reduction in the runoff product retained on the
template in Spt5-depleted extracts is due to an increase in
transcript release at the terminator sequence, . Densitometry
of the gels (Fig. 3B) shows that in the absence of Spt5 there is
a 3.3-fold increase in the amount of RNA released at the
terminator and a concomitant 13.4-fold decrease in the
amount of RNA released from the end of the template.
Spt5 does not promote transcript release at arrest sites. To
test whether Spt5 can help to overcome blocks imposed by
strong arrest sites, we also prepared templates carrying arrest
sites present in the human histone H3.3 gene intron (Fig. 4).
These sequences contain two tandem polypyrimidine tracts
flanked by purines. The effect of these sequences is to bend the
DNA and force polymerase pausing (4, 30). As a control, we
also included a template that did not carry either the artificial
terminator or the strong arrest sites.
As shown in Fig. 4, the stem-loop terminator sequence in-
duced pausing at 290 () whereas the histone H3.3 arrest
sequence introduced two new stop sites of the expected sizes
that were absent at the equivalent positions on the control
template. During the transcription reaction, using mock-de-
pleted extracts, Tat increased the synthesis of long transcripts
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FIG. 2. Efficient elongation from transcription complexes paused at 14 requires the addition of nuclear extract. (A) Preinitiation complexes
were set up on immobilized templates as described in the legend to Fig. 1 and paused at 14 by elongation in the presence of CTP, GTP, and
[-32P]UTP. The 14 products were then washed and chased by addition of unlabeled nucleotides. Reactions were performed in the absence ()
or presence () of 10 l of fresh nuclear extract (NE) and of 20 ng of Tat protein. RNA products tightly associated with the elongation complexes
(bound) or prematurely released from the template (free) were analyzed: Abbreviations: TAR, paused transcription complexes or transcripts
released at 59, at the end of the TAR stem-loop structure; Stem II, complexes released at 104, at the end of stem-loop II in the HIV sequence;
, paused transcription complexes or transcripts released at the terminator; 	, transcripts reaching the end of the template. (B) Transcription in
the presence of NF-
B. Recombinant NF
B p65 protein (300 ng) purified from baculoviruses () or the corresponding storage buffer (NDBZ
buffer; see Materials and Methods) () was added prior to the nuclear extract to set up the preinitiation complex. Transcription was then carried
out to pause the complexes at14, and beads were washed and then chased in the presence of fresh nuclear extract and the absence () or
presence () of 20 ng of Tat. Bound or released (free) RNA products were analyzed.
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on each of the templates by more than 15-fold and greatly
enhanced readthrough of both the terminator sequence and
the histone arrest sites. Consistent with the results shown in
Fig. 3, when the same reactions were performed using Spt5-
depleted extracts, there was a three- to fourfold increase in the
amount of transcripts released at the terminator site present in
pW1.
By contrast, there was no transcript release using the pH3.3
templates. However, an approximately twofold increase in the
amount of paused transcription complexes was found at the
arrest sites when transcription was performed in the absence of
Spt5. Similarly, increased pausing at strong arrest sites found in
the HIV sequence was observed when the control template was
transcribed in the absence of Spt5.
FIG. 3. Spt5 prevents release of transcripts at terminator sequences. (A) Standard transcription reactions using an immobilized wild-type HIV-1
LTR template with either a mock-depleted (Mock) or Spt5-depleted (Spt5) nuclear extract (NE), in the absence () or presence () of 20 ng
of Tat. RNA products present in elongation complexes (bound fraction) as well as released transcripts (free fraction) were analyzed. (B) Den-
sitometry of the gels shown in panel A. Continuous line, mock-depleted extracts in the presence of Tat; broken line, Spt5-depleted extracts in the
presence of Tat.
FIG. 4. Spt5-enhanced readthrough of transcription arrest sites. Three different templates were used in this experiment: the wild-type HIV-1
LTR (pW1), which contains the artificial stem-loop terminator sequence; constructs in which the terminator sequence has been replaced by an
arrest sequence present in the histone H3.3 gene (H3.3); and a control sequence (control). Standard transcription reactions using the three
different immobilized templates with either a mock-depleted (Mock) or a Spt5-depleted (Spt5) nuclear extract (NE), in the absence () or
presence () of 20 ng of Tat, were performed. RNA products present in elongation complexes (bound fraction) as well as released transcripts (free
fraction) are shown.
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We interpret these results as indicating that Spt5 is able to
relieve pausing at a wide variety of sites ranging from the
naturally occurring pause sites on the control templates to the
strong arrest sites on the H3.3 template and the strong termi-
nator sequence present in pW1. Thus, using the pW1 template,
full-length transcript levels were reduced 2.9-fold when Spt5
was removed. Similarly, full-length transcript levels were re-
duced 1.6- and 2.4-fold in the absence of Spt5 when the pH3.3
and control templates were used.
TAK and Spt5 play distinct and complementary roles dur-
ing elongation. Tat activation of elongation requires TAK
(p-TEFb), a kinase that is able to phosphorylate the RNA
polymerase CTD as well as to relieve blocks imposed during
early elongation by Spt5 (DSIF). Immunodepletion of tran-
scription reactions of the CDK9 subunit of TAK has been
reported previously to severely inhibit Tat-dependent elonga-
tion and reduce basal transcription (9, 66), but the relative
contributions of TAK and Spt5 to the elongation reaction have
not been measured.
In the experiment in Fig. 5, we took advantage of the ob-
servation that early-stage elongation complexes paused at 14
could be efficiently prepared using extracts in which both TAK
(CDK9 and CycT1) and Spt5 were depleted. The immunoblots
shown in Fig. 5B demonstrate that CDK9, CycT1, and Spt5 can
be removed from the extracts both individually and without
significantly depleting the extracts for other transcription fac-
tors, including TAFII250, RNA polymerase II, CDK7, and
RAP74.
It is important to note that depletion of Spt5 in this system
does not impair the synthesis of the 14 transcripts (Fig. 5;
also see Fig. 8). These observations are consistent with earlier
reports showing that NELF and DSIF have only minimal ef-
fects on early-stage elongation reactions (62). Thus, Spt5 is not
required for initiation or early elongation. The paused tran-
scription complexes prepared in the absence of TAK and Spt5
could then be chased in the presence and absence of mock-
depleted, TAK-depleted, and Spt5-depleted nuclear extracts.
Under these conditions, efficient elongation and Tat responses
were obtained using the mock-depleted extracts in the chase
(Fig. 5A). However, there was a severe restriction in the for-
mation of long transcripts when TAK was depleted. As ex-
pected, in the absence of TAK, Tat was also unable to stimu-
late elongation. By contrast, Tat was able to stimulate
elongation in the absence of Spt5, but the overall levels of long
transcripts were reduced due to enhanced pausing and RNA
chain release at the terminator sequence. Thus, the comple-
mentary activities of TAK, Tat, and Spt5 are evident at the
terminator sequence. Tat and TAK were able to stimulate the
production of runoff templates, but the total amount of these
products was strongly reduced in the absence of Spt5 due to
the increased release of transcripts at the terminator sequence.
In addition to transcript release at the terminator, a signif-
icant amount of transcripts of approximately 60 nucleotides
(nt) was released at the end of the TAR RNA sequence and
after the end of stem-loop II. It is notable that equivalent levels
of released TAR were observed when mock-depleted, TAK-
depleted, and Spt5-depleted extracts were used. Thus, neither
Spt5 nor TAK plays a significant role in stabilizing transcrip-
tion complexes at TAR.
Tat-dependent hyperphosphorylation of Spt5 in late-stage
elongation complexes. We have reported previously (21) that
RNA polymerase, which is mainly unphosphorylated in the
nuclear extract (IIa), becomes phosphorylated during early
elongation (IIo) and hyperphosphorylated in the presence of
Tat after transcription through TAR (IIo*) (Fig. 6A). Immu-
noblotting of the elongation complexes with Spt5-specific an-
tibodies (Fig. 6A) demonstrated that Spt5 also becomes phos-
phorylated in parallel to the RNA polymerase II CTD.
Addition of Tat to the reaction mixture induced the appear-
ance of a second band migrating above Spt5, which we have
called Spt5*. This shift in the migration of Spt5 is dependent
on a functional TAR element, as shown with templates carry-
ing a point mutation either in the Tat-binding site (mGC) or in
the cyclin T1-binding site (mLG).
Treatment of the elongation complexes with protein phos-
phatase 1 results in the complete disappearance of the band
corresponding to the Spt5* protein (Fig. 6B), demonstrating
that Spt5* is a form of Spt5 which is modified by phosphory-
lation. It should also be noted that the migration of the Spt5
protein present in the elongation complexes in the absence of
Tat was slightly decreased compared to that of the dephospho-
rylated protein. This suggests that Spt5 is partially phospho-
rylated in these complexes and that Tat induces a further
phosphorylation of the protein after its binding to the TAR
element.
Reports published when these experiments were in progress
have also demonstrated that Spt5 can become phosphorylated
during transcription elongation (31, 47). However, these ex-
periments were performed by adding limiting amounts of 32P-
labeled nucleotides to arrested transcription complexes and
consequently underestimated the extent of phosphorylation
that Spt5 undergoes during elongation in the presence of Tat.
As a result, the Spt5* form was not detected in these earlier
experiments. In agreement with our results, a highly phospho-
rylated form of Spt5, which may correspond to Spt5*, was
detected by Garber et al. (15) after the in vitro phosphoryla-
tion of Spt5 by CDK9.
Recruitment of Spt5 to early-stage transcription elongation
complexes. The elongation factor Spt5 has been identified pre-
viously as necessary for Tat-dependent transactivation of the
transcription from the LTR promoter (61). To measure the
dynamics of Spt5 association with transcription complexes dur-
ing various stages of the transcription cycle, preinitiation, 14,
and elongation complexes were analyzed by immunoblotting.
Antibodies against TAK (CDK9 and cyclin T1) and the CTD-
associated kinase (CDK7 and cyclin H) were used as controls
(Fig. 6).
Surprisingly only background levels of Spt5 were observed in
preinitiation complexes (Fig. 6C). However, in agreement with
the observations of Ping and Rana (47), we found that Spt5
was recruited shortly after initiation and was present at high
levels in the transcription complexes paused at 14. By con-
trast, control experiments show that the CTD-associated ki-
nase subunits CDK7 and cyclin H were present at high levels in
preinitiation complexes but were then recycled during tran-
scription. These factors are found at significantly reduced lev-
els in the complexes paused at 14 and are essentially absent
from complexes that have extended beyond 14 (33, 64, 65).
Both CDK9 and its associated cyclin T1 were present in the
complex assembled on the DNA template during initiation,
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FIG. 5. Complementary activities of Spt5 and TAK during elongation. (A) Elongation complexes arrested at 14 were prepared using a nuclear
extract depleted of both TAK and Spt5. The 14 complexes were washed and subsequently chased in the presence of either mock-depleted
(Mock), TAK-depleted (TAK), or Spt5-depleted (Spt5) nuclear extracts (NE). Each chase was performed in the absence () or presence ()
of 20 ng of Tat protein. RNA products present in elongation complexes (bound fraction) as well as released transcripts (free fraction) were
analyzed. (B) Immunoblot showing the protein composition of depleted nuclear extracts. A corresponding amount of each nuclear extract was
analyzed by immunoblotting using antibodies directed against the following proteins (from top to bottom): TAFII250, the core of RNA polymerase
II (Pol II) (N-20), Spt5 (anti-DSIF-p160), cyclin T1, CDK9, CDK7, and RAP74.
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and no change in their levels were observed during subsequent
elongation.
Spt5 is not required for activation of TAK by Tat. The
observation that there was still a significant increase in tran-
scription elongation on addition of Tat to Spt5-depleted ex-
tracts (Fig. 3 to 5) suggests that Tat and Spt5 are operating
through distinct biochemical mechanisms but show comple-
mentary functions. In support of this hypothesis, the immuno-
blotting experiment in Fig. 7 demonstrates that although Spt5
is phosphorylated by CDK9 during elongation, it is not re-
quired for the activation of CDK9 by Tat.
Figure 7A shows the effects of immunodepletion of CDK9
and cyclin T1 on protein phosphorylation. In these extracts,
transcription initiation was normal and there was no reduction
in the levels of transcripts reaching 14. However, removal of
CDK9 and cyclin T1 strongly inhibited Tat-activated elonga-
tion in the subsequent chase (data not shown). As shown in
Fig. 7A, immunodepletion of CDK9 and cyclin T1 also resulted
in a complete absence of both the RNA polymerase IIo* and
the Spt5* proteins from elongation complexes prepared in the
presence of Tat. Thus, both RNA polymerase II and Spt5 are
substrates for CDK9 during Tat-activated transcription.
In contrast, depletion of CDK7 resulted in a severe inhibi-
tion of transcription initiation (data not shown). Under these
conditions, there was a strong reduction in the levels of RNA
polymerase IIo and polymerase IIo, with approximately 50%
of the template-associated RNA polymerase remaining hypo-
phosphorylated (IIa), and a corresponding reduction in Spt5
levels. However, due to some residual initiation events, some
of the Spt5 that was recruited to the promoter became phos-
phorylated by CDK9 during elongation.
Significantly, in the Spt5-depleted extracts (Fig. 7B), hyper-
phosphorylation of the RNA polymerase CTD took place with
the same efficiency as in mock-depleted extracts. Thus, the
defects in elongation observed in the absence of Spt5 cannot be
attributed to changes in the phosphorylation pattern of RNA
polymerase. Furthermore, the experiment shows that although
Spt5 is itself a substrate for the Tat-activated CDK9, it is not
required for the phosphorylation of the CTD by CDK9 and
does not appear to act as a regulator of CDK9 activity.
Spt5 is not required for initiation or early elongation. To
examine whether Spt5 is required for initiation or early elon-
gation, we also examined the synthesis of the 14 transcripts
using mock-depleted and Spt5-depleted extracts. The reactions
in Fig. 8 were performed using three different concentrations
of dATP to regulate the level of CDK7-dependent phospho-
FIG. 6. Spt5 is recruited shortly after initiation and hyperphosphorylated during elongation in the presence of Tat. (A) Immunoblot showing
the protein composition of elongation complexes. Standard transcription reactions were performed using templates carrying either wild-type (WT),
bulge (mGC), or loop (mLG) mutants of the TAR element, in the presence of 100 ng of LacR and in the absence () or presence () of 20 ng
of Tat. Elongation complexes were purified and analyzed with antibodies directed (from top to bottom) against the core of RNA polymerase II
(N-20), Spt5 (provided by R. Gaynor) or LacR (NL1.1B2.10). Tat induces hyperphosphorylation of both RNA polymerase (IIo*) and Spt5 (Spt5*).
A 1-l volume of nuclear extract (E) was used as a control. (B) Phosphatase treatment of elongation complexes. Elongation complexes purified
as in panel A were incubated in the absence () or presence () of protein phosphatase 1 (PP1) and analyzed by immunoblotting with Spt5
antibodies. (C) Immunoblot showing the protein composition of the different transcription complexes. PIC and 14 complexes were assembled
on wild-type immobilized template and purified as described in the legend to Fig. 1. Elongation complexes were purified from parallel standard
transcription reactions, using templates carrying wild-type or mutant (mGC) TAR. Tat was added () or not () at different times to monitor its
effect in different complexes. Purified complexes were loaded on precast gels of appropriate concentration for analysis of different proteins and
probed with the corresponding antibodies (from top to bottom): Spt5 (provided by R. Gaynor), the core of RNA polymerase II (N-20), CDK9
(H-169), cyclin T1 (C-20), CDK7 (C-19), and cyclin H (D-10).
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rylation in the preinitiation complexes. At 5 and 10 M dATP,
synthesis of the 14 complex was strongly inhibited compared
to the levels obtained using 25 M dATP.
At dATP concentrations below 25 M, the phosphorylation
of the RNA polymerase CTD in the preinitiation complex was
restricted and the majority of the RNA polymerase remained
unphosphorylated. During the subsequent chase there was ad-
ditional phosphorylation of the RNA polymerase CTD, and
the amount of the RNA polymerase IIo form that was pro-
duced was equivalent to that seen in the presence of 25M
dATP. We attribute the additional CTD phosphorylation to
the use of GTP in the chase mixture by CDK7 and/or confor-
mational changes that are induced in the RNA polymerase
during the synthesis of the first residues of the nascent tran-
script. However, at dATP concentrations below 25 M, the
formation of the 14 complex was strongly inhibited. This
result is consistent with studies showing that although the CTD
kinase activity of TFIIH enhances initiation rates, it is not
obligatory for initiation and early elongation (55). The dATP-
dependent increase in early elongation most probably re-
flects the increasing ability of the XPB subunit of TFIIH to
use dATP as a substrate for its ATP-dependent helicase
activity, which is the main enzymatic activity required for
initiation (7, 55).
As noted above, Spt5 is not present in the preinitiation
complexes but is recruited to early-stage elongation complexes.
As shown in Fig. 8, there is a strict correlation between the
amount of Spt5 recruitment and the amount of 14 RNA
synthesis. However, there is no correlation between Spt5 re-
cruitment and the extent of RNA polymerase CTD phospho-
rylation. It therefore seems likely that Spt5 is recruited to early
elongation complexes because of conformational changes in
the polymerase rather than because of recognition of the phos-
phorylated form of the CTD.
FIG. 7. Spt5 is not required for Tat-dependent hyperphosphorylation of RNA polymerase II. (A) Elongation complexes were assembled using
mock-depleted extracts (Mock) or immunodepleted extracts with anti-CDK7 antibodies (CDK7) or a combination of antibodies against CDK9
and cyclin T1 (TAK). The complexes were analyzed by Western blotting using antibodies directed against (from top to bottom) Spt5 (provided
by R. Gaynor), the core of RNA polymerase II (N-20), CDK7 (C-19), CDK9 (H-169), and cyclin T1 (C-20). (B) Elongation complexes were
assembled using mock-depleted extracts or extracts immunodepleted of Spt5 and analyzed with antibodies directed against (from top to bottom)
the core of RNA polymerase II (N-20), Spt5 and CDK9 (H-169). NE, nuclear extract.
FIG. 8. Spt5 recruitment is independent of RNA polymerase II phosphorylation. (A) PIC and early elongation complexes (14) were
assembled as described in the legend to Fig. 1, using mock-depleted (Mock) or Spt5-depleted (Spt5) nuclear extract (NE) pretreated with HK
and glucose, and in the presence of increasing levels of dATP (5, 10, or 25 M). The protein compositions of the different transcription complexes
were analyzed by Western blotting with core RNA polymerase II (N-20)- or Spt5 (provided by R. Gaynor)-specific antibodies. (B) Transcription
gel showing the corresponding 14 RNA products. Note that RNA polymerase can be extensively phosphorylated under conditions that do not
permit formation of the 14 products. Spt5 is recruited proportionally to the amount of the 14 product.
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Positive and negative roles for Spt5 during transcription
elongation. The human homologue of Spt5 was first identified
as one of the subunits of DSIF, a factor that could mediate the
inhibition of transcriptional elongation in the presence of the
protein kinase inhibitor DRB (59). DSIF induces promoter-
proximal pausing when CDK9 kinase activity is absent, such as
in extracts that have been immunodepleted of CDK9 or in
extracts that have been treated with DRB (58, 59). This elon-
gation block is relieved by addition of purified p-TEFb (58)
together with a second factor called NELF (negative elonga-
tion factor) (62).
In an independent study pointing to a positive role for Spt5
in transcription elongation, Wu-Baer et al. (61) discovered that
Spt5 is an essential cofactor for Tat activation of HIV tran-
scription elongation. Studies of the Drosophila heat shock pro-
moter also indicate that Spt5 can play a role in general elon-
gation (2). Spt5 is present at the promoter in the absence of
heat shock, suggesting that it might be associated with the
paused transcription complex or that it might play a role in
maintaining the chromatin structure under an open conforma-
tion. Following heat shock, Spt5 is redistributed to occupy both
the 5 and 3 ends of heat shock genes, where it colocalizes with
RNA polymerase and p-TEFb (2). This association with active
transcription complexes suggests that Spt5 can also play a
positive role in transcription elongation. Consistent with this
hypothesis, Drosophila Spt5 colocalizes extensively with the
actively elongating IIo form of RNA polymerase and with p-TEFb
on polytene chromosomes (25).
Spt5 is a general elongation factor that stabilizes RNA poly-
merase at terminator sequences. In this study we used immo-
bilized DNA template to analyze the role of Spt5 during the
transactivation of the HIV-1 LTR transcription in detail. Using
a three-stage transcription assay, we demonstrated that Spt5 is
not present in preinitiation complexes but that it is recruited
immediately after initiation, independently of Tat. Our studies
have also shown that Spt5 plays a positive role in transcription
elongation by enhancing the stability of transcription com-
plexes at terminator sequences and by promoting readthrough
of strong arrest sites. In the absence of Spt5, release of tran-
scripts at terminator sites is increased over threefold, while
polymerase pausing at bent DNA sequences is increased by as
much as twofold.
This novel biochemical function of Spt5 is reminiscent of
that activity of the E. coli NusG protein, with which it has a
region of sequence homology. NusG is an essential E. coli
protein that regulates Rho-dependent termination by increas-
ing the rate of transcription of elongation of E. coli RNA
polymerase in the absence of Rho. This renders the transcrip-
tion complex more susceptible to the termination activity of
Rho and leads to early chain release (45). NusG selectively
reduces transcription pausing at class II terminators, a set of
pause sites where less stable RNA-DNA hybrids induce back-
tracking of RNA polymerase (3). In the experiments reported
here, the  terminator sequence, which consists of a stable
stem-loop structure followed by a tract of nine U residues, has
a structure and activity similar to those of the class II termi-
nators. Moreover, release of RNA from the template in the
absence of Spt5 occurs preferentially at the end of the poly(U)
tract, where the RNA-DNA hybrid is expected to be particu-
larly unstable.
Genetic and biochemical studies have shown that Spt5, like
NusG, interacts directly with RNA polymerase II (19, 59, 61,
62). The interactions between Spt5 and RNA polymerase II
are mediated by four KOW domains, which are also found in
NusG (18). Significantly, deletion of one of the two N-terminal
KOW motifs also resulted in loss of Spt5 activity. It is not yet
known whether, by analogy to NusG, Spt5 complements the
function of a Rho-like termination factor or whether it acts
directly on the RNA polymerase to stabilize it at terminator
sequences.
Spt5 does not induce transcript release after TAR. In the
original experiments used to characterize DSIF function,
Wada et al. (58, 59) found that addition of DSIF to partially
reconstituted transcription systems resulted in promoter-prox-
imal pausing, creating a series of early termination products of
20 to 30 nt. This negative effect seems to be a specific feature
of the partially purified transcription system and specific reac-
tion conditions used in these experiments. Subsequent studies
by Yamaguchi et al. (62) have shown that blocks to elongation
imposed by DSIF and NELF become apparent only during the
later stages of elongation, when RNA polymerase has tran-
scribed at least 60 nt. These effects of DSIF and NELF are
largely kinetic, and over time only full-length transcripts are
produced even in the absence of DSIF (49).
In HIV, the TAR RNA sequence is located within the first
59 nt of the transcript and forms a strong kinetic barrier to
elongation (41, 42). In our experiments, using HeLa cell nu-
clear extracts depleted of either Spt5 or CDK9, we could find
no evidence that Spt5 moderated the promoter-proximal paus-
ing of transcription release at the TAR RNA sequence. By
contrast, we have found evidence that transcription elongation
factors other than Spt5 are required for early stability of elon-
gation, particularly after stem-loop structures such as TAR
RNA and stem-loop II. When 14 complexes are chased in the
absence of added nuclear extract, the majority of the RNA
polymerases disengage from the template near the end of the
TAR RNA. This block to elongation can be relieved by the
addition of nuclear extracts, including extracts that have been
depleted of Spt5. Although the identity of these factors has not
yet been established, it seems very likely that the general elon-
gation factors TFIIF and TFIIS, which are known to stimulate
transcription from the HIV LTR in cell-free systems, are also
able to contribute to polymerase stability during HIV elonga-
tion through TAR (27).
Regulation of Spt5 by phosphorylation. It is now well estab-
lished that DSIF activity is regulated by phosphorylation. For
example, addition of CDK9 to depleted extracts is able to
restore DRB-independent inhibition of transcription by DSIF
and NELF (57–59, 62).
Spt5 contains two separate domains named CTR1 and
CTR2, which show some sequence similarity to the RNA poly-
merase II CTD (63). The CTR1 motif is well conserved and
contains nine repeats of the consensus sequence GS(R/Q)T
PXY. The CTR2 motif is less well conserved and has 10 re-
peats of the consensus P(T/S)PSP(Q/A)(S/G)Y. Spt5 is a
known substrate for phosphorylation by CDK9 in vitro (15,
22). This phosphorylation is restricted mainly to CTR1; how-
ever, the functional significance of the various phosphorylation
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FIG. 9. Model for the activity of Spt5 in the Tat-mediated transactivation of transcription at the HIV-1 LTR promoter. (A) Initiation. The
RNA polymerase II (Pol II) complex, containing all the general transcription factors assembles on the promoter (only TFIID and TFIIH are
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sites has not been unambiguously established. In one study,
DRB-sensitive transcription was unaffected by deletion of the
C-terminal region (63); however, a second report suggested
that CTR1 conferred DRB sensitivity (22).
Here we have provided additional evidence that phospho-
rylation of Spt5 by CDK9 is important for its activity. We have
shown that Spt5 becomes highly phosphorylated in elongation
complexes that have been activated by Tat. This results in the
appearance of a modified form of the protein with markedly
reduced mobility in SDS-polyacrylamide gels (Spt5). Earlier
experiments showing that Spt5 can become phosphorylated
during transcription elongation (31, 47) were performed under
limiting nucleotide concentrations and underestimated the ex-
tent to which the protein is phosphorylated. The hyperphos-
phorylation of Spt5 does not occur when CDK9 and cyclin T1
are immunodepleted from the nuclear extracts or when Tat is
absent from the system, suggesting strongly that Tat-activated
CDK9 is the kinase responsible for Spt5 hyperphosphorylation.
Phosphatase treatment showed also that Spt5 is partially
phosphorylated in early elongation complexes that have not
been exposed to Tat or transcribed through TAR RNA. Sig-
nificantly, this form of the protein can also be detected in the
absence of CDK9, implying that another kinase is able to
phosphorylate Spt5 when it is recruited to early elongation
complexes. In keeping with these observations, Ivanov et al.
(22) reported that CDK7 is able to phosphorylate Spt5 carry-
ing mutations in the CTR1 domain. This suggests that addi-
tional phosphorylation sites located outside the CTR regions
could be subject to modification by protein kinases other than
CDK9.
Recruitment of Spt5 to early-stage elongation complexes.
Spt5 is not present in preinitiation complexes but is recruited
shortly after initiation. Although it was originally proposed
that Spt5 could interact only with the nonphosphorylated form
of RNA polymerase II (58), our results suggest strongly that
Spt5 is recruited following CTD phosphorylation and tran-
scription initiation. A clear demonstration of the separation
between CTD phosphorylation and Spt5 recruitment is found
in the experiment in Fig. 8. In this experiment, preinitiation
complexes were formed under conditions that limit initiation
due to restricted levels of dATP. In subsequent chases in the
absence of additional ATP, the RNA polymerase CTD be-
comes fully phosphorylated due to CDK7 activity but initiation
is compromised and only a small fraction of the polymerases
are able to transcribe up to 14. Under these conditions, there
is a strict correlation between the amount of Spt5 that is re-
cruited and the levels of 14 transcripts but there is no re-
cruitment of Spt5 to the phosphorylated RNA polymerases
remaining at the promoter. Thus, it appears that Spt5 is re-
cruited to early elongation complexes because of conforma-
tional changes in the polymerase and/or its release from initi-
ation factors that permits Spt5 binding rather than recognition
of the phosphorylation state of the CTD. In keeping with this
hypothesis, we have also found that dephosphorylation of the
14 transcription complexes does not result in release of Spt5
(data not shown).
Complementary roles of Spt5 and TAK during HIV-1 LTR
transcription. How do Spt5 and TAK act in concert to pro-
mote efficient elongation? In both prokaryotes and eukaryotes,
transcription elongation is discontinuous and is characterized
by multiple and specific pausing events. The duration of these
pauses is a function of the specific DNA sequences being
transcribed as well as of interactions with regulatory proteins.
In this study we examined the effects of Spt5 and TAK on
transcription through a variety of blocks to elongation. The
first transcription block that we studied was an RNA stem-loop
structure followed by 9 uridine residues. This artificial se-
quence, which closely resembles bacterial termination signals,
causes RNA polymerase to stop elongation and to release
transcripts in cell-free transcription systems. The second tran-
scription block was an arrest site normally found in the histone
H3.3 gene. This site carries structural elements that bend DNA
and causes polymerase pausing but not the release of the
nascent transcripts in cell-free systems and in vivo (4, 30). Bent
DNA sequences are also potent arrest sites in yeast (10, 32).
The heterologous terminator and arrest sequences that we
have used in these experiments provide effective tools for mea-
suring small changes in RNA polymerase processivity. How-
ever, the HIV genome does not carry any specific termination
signals. Instead, there are numerous sites where pausing can
occur. The cumulative effect of each of these pauses is to
prevent the RNA polymerase from transcribing the entire HIV
genome unless Tat and Spt5 are present. Enhancement of
elongation therefore involves not only increasing the intrinsic
processivity of the polymerase but also ensuring that the acti-
vated polymerase remains tightly bound to the template (56).
The results presented in this paper strongly suggest that Spt5
helps to stabilize RNA polymerase during elongation and
thereby functions as a cofactor for Tat.
As shown in the model presented in Fig. 9, it seems likely
that phosphorylation of the RNA polymerase CTD and Spt5
by Tat-activated CDK9 are two separate activation events. In
agreement with our previous results (21), we have shown that
CDK9 and cyclin T1 are present at equivalent levels in the
preinitiation complexes and transcription complex during var-
ious stages of elongation. However, immunodepletion experi-
ments show that CDK9 is required only for late elongation, not
for HIV-1 transcription initiation or early elongation. CDK9
represented). CDK9 and cyclin T1 are also present in the complex but are inactive (blue boxes). During initiation, the CTD of RNA polymerase
is extensively phosphorylated by the CDK7 subunit of TFIIH. (B) Pausing at 14. Shortly after initiation, as measured by the 14 complexes, Spt5
is recruited to the transcription complex. Assembly of the 14 complex and phosphorylation of the CTD by TFIIH are equivalent in the presence
and absence of Spt5. (C) Tat binds TAR RNA and activates TAK. Shortly after promoter clearance, the general transcription factors, including
TFIIH, dissociate from the transcription complex. After the transcription of the TAR element, Tat is recruited and activates TAK (the CDK9 and
CycT1 complex represented by blue circles). The active kinase complex phosphorylates both the CTD of RNA polymerase II (II0* form) and Spt5
(Spt5*). (D) Highly processive transcription complex. In the presence of Spt5, the highly processive transcription complex formed after Tat-
mediated activation is stabilized and can carry out the transcription of the full HIV genome. (E) Release of the transcript at the terminator. In
the absence of Spt5, the transcription complex containing a highly phosphorylated RNA polymerase II is less stable than complexes containing
Spt5. As a result, there is an increased rate of release of transcripts at pause sites, such as the terminator sequence ().
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activity does not appear to be required to enhance polymerase
stability on templates. Depletion of extracts of CDK9 and
CycT1 blocks Tat-activated transcription but does not result in
premature release of transcripts, suggesting that TAK is re-
quired to enhance polymerase processivity directly. Consistent
with this hypothesis, we have found in experiments to be pre-
sented elsewhere (Y. K. Kim et al., unpublished data) that
CTD phosphorylation can enhance the ability of RNA poly-
merase to read through terminator sequences.
The role of Spt5 appears to be complementary to but distinct
from the activation of elongation by CTD phosphorylation.
Like CDK9, Spt5 is not required for initiation or during the
early stages of elongation and can be recruited to complexes
paused at 14. Furthermore, in the HIV system, Spt5 is not
required for basal transcription from the HIV LTR and there
is no evidence for an increase of short transcripts in Spt5-
depleted extracts. However, as shown here, Spt5 is required to
prevent premature release of RNA chains from specific termi-
nator sequences and minimize arrest at bent DNA sequences.
It is this novel biochemical function of Spt5 that permits it to
play a critical role in promoting Tat-dependent transcriptional
elongation.
ACKNOWLEDGMENTS
We thank our colleague Marc Bailey for helpful discussions, and we
thank A. D. Lowe for preparation of the transcription cell extracts. We
are grateful to Richard Gaynor, Jim Hiscott, and Tsafi Pe’ery for gifts
of reagents.
REFERENCES
1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and
M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-
associated retrovirus in human and non-human cells transfected with an
infectious molecular clone. J. Virol. 59:284–291.
2. Andrulis, E. D., E. Guzmán, P. Döring, J. Werner, and J. T. Lis. 2000.
High-resolution localization of Drosophila Spt5 and Spt6 at heat shock genes
in vivo: roles in promoter proximal pausing and transcription elongation.
Genes Dev. 14:2635–2649.
3. Artsimovitch, I., and R. Landick. 2001. Pausing by bacterial RNA polymer-
ase is mediated by mechanistically distinct classes of signals. Proc. Natl.
Acad. Sci. USA 97:7090–7095.
4. Awrey, D. E., R. G. Weilbaecher, S. A. Hemming, S. M. Orlicky, C. M. Kane,
and A. M. Edwards. 1997. Transcription elongation through DNA arrest
sites: a multistep process involving both RNA polymerase II subunit RPB9
and TFIIS. J. Biol. Chem. 272:14747–14754.
5. Berkhout, B., R. H. Silverman, and K.-T. Jeang. 1989. Tat trans-activates the
human immunodeficiency virus through a nascent RNA target. Cell 59:273–
282.
6. Bieniasz, P. D., T. A. Grdina, H. P. Bogerd, and B. R. Cullen. 1998. Recruit-
ment of a protein complex containing Tat and cyclin T1 to TAR governs the
species specificity of HIV-1 Tat. EMBO J. 17:7056–7065.
7. Bradsher, J., F. Coin, and J.-M. Egly. 2000. Distinct roles for the helicases
of TFIIH in transcript initiation and promoter escape. J. Biol. Chem. 275:
2532–2538.
8. Chen, D., Y. Fong, and Q. Zhou. 1999. Specific interaction of Tat with the
human but not rodent pTEFb complex mediates the species-specific Tat
activation of HIV-1 transcription. Proc. Natl. Acad. Sci. USA 96:2728–2733.
9. Chen, D., and Q. Zhou. 1999. Tat activates human immunodeficiency virus
type 1 transcriptional elongation independent of TFIIH kinase. Mol. Cell.
Biol. 19:2863–2871.
10. Christie, K. R., D. E. Awrey, A. M. Edwards, and C. M. Kane. 1994. Purified
yeast RNA polymerase II reads through intrinsic blocks to elongation in
response to the yeast TFIIS analogue, p37. J. Biol. Chem. 269:936–943.
11. Churcher, M. J., A. D. Lowe, M. J. Gait, and J. Karn. 1995. The RNA
element encoded by the trans-activation-responsive region of human immu-
nodeficiency virus type 1 is functional when displaced downstream of the
start of transcription. Proc. Natl. Acad. Sci. USA 92:2408–2412.
12. Dingwall, C., I. Ernberg, M. J. Gait, S. M. Green, S. Heaphy, J. Karn, A. D.
Lowe, M. Singh, M. A. Skinner, and R. Valerio. 1989. Human immunodefi-
ciency virus 1 Tat protein binds trans-activation-responsive region (TAR)
RNA in vitro. Proc. Natl. Acad. Sci. USA 86:6925–6929.
13. Fujinaga, K., R. Taube, J. Wimmer, T. P. Cujec, and B. M. Peterlin. 1999.
Interactions between human cyclin T, Tat, and the transactivation response
element (TAR) are disrupted by a cysteine to tyrosine substitution found in
mouse cyclin T. Proc. Natl. Acad. Sci. USA 96:1285–1290.
14. Garber, M. E., and K. A. Jones. 1999. HIV-1 Tat: coping with negative
elongation factors. Curr. Opin. Immunol. 11:460–465.
15. Garber, M. E., T. P. Mayall, E. M. Suess, J. Meisenhelder, N. E. Thompson,
and K. A. Jones. 2000. CDK9 autophosphorylation regulates high-affinity
binding of the human immunodeficiency virus type 1 Tat-P-TEFb complex to
TAR RNA. Mol. Cell Biol. 20:6958–6969.
16. Garber, M. E., P. Wei, V. N. KewelRamani, T. P. Mayall, C. H. Herrmann,
A. P. Rice, D. R. Littman, and K. A. Jones. 1998. The interaction between
HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue
that is not conserved in the murine CycT1 protein. Genes Dev. 12:3512–
3527.
17. Graeble, M. A., M. J. Churcher, A. D. Lowe, M. J. Gait, and J. Karn. 1993.
Human immunodeficiency virus type 1 trans-activator protein Tat, stimulates
transcriptional read-through of distal terminator sequences in vitro. Proc.
Natl. Acad. Sci. USA 90:6184–6188.
18. Greenblatt, J., J. R. Nodwell, and S. W. Mason. 1993. Transcriptional anti-
termination. Nature 364:401–406.
19. Hartzog, G. A., T. Wada, H. Handa, and F. Winston. 1998. Evidence that
Spt4, Spt5, and Spt6 control transcription elongation by RNA polymerase II
in Saccharomyces cerevisiae. Genes Dev. 12:357–369.
20. Herrmann, C. H., and A. P. Rice. 1995. Lentivirus Tat proteins specifically
associate with a cellular protein kinase, TAK, that hyperphosphorylates the
carboxyl-terminal domain of the large subunit of RNA polymerase II: can-
didate for a Tat cofactor. J. Virol. 69:1612–1620.
21. Isel, C., and J. Karn. 1999. Direct evidence that HIV-1 Tat activates the
Tat-associated kinase (TAK) during transcriptional elongation. J. Mol. Biol.
290:929–941.
22. Ivanov, D., Y. T. Kwak, J. Guo, and R. B. Gaynor. 2000. Domains in the SPT5
protein that modulate its transcriptional regulatory properties. Mol. Cell.
Biol. 20:2970–2983.
23. Ivanov, D., Y. T. Kwak, E. Nee, J. Guo, L. F. Garcia-Martinez, and R. B.
Gaynor. 1999. Cyclin T domains involved in complex formation with Tat and
TAR RNA are critical for Tat-activation. J. Mol. Biol. 288:41–56.
24. Kao, S.-Y., A. F. Calman, P. A. Luciw, and B. M. Peterlin. 1987. Anti-
termination of transcription within the long terminal repeat of HIV-1 by Tat
gene product. Nature 330:489–493.
25. Kaplan, C. D., J. R. Morris, C.-T. Wu, and F. Winston. 2000. Spt5 and Spt6
are associated with active transcription and have characteristics of general
elongation factors in D. melanogaster. Genes Dev. 14:2623–2634.
26. Karn, J. 1999. Tackling Tat. J. Mol. Biol. 293:235–254.
27. Kato, H., H. Sumimoto, P. Pognonec, C.-H. Chen, C. A. Rosen, and R. G.
Roeder. 1992. HIV-1 Tat acts as a processivity factor in vitro in conjunction
with cellular elongation factors. Genes Dev. 6:655–666.
28. Keen, N. J., M. J. Churcher, and J. Karn. 1997. Transfer of Tat and release
of TAR RNA during the activation of the human immunodeficiency virus
type-1 transcription elongation complex. EMBO J. 16:5260–5272.
29. Keen, N. J., M. J. Gait, and J. Karn. 1996. Human immunodeficiency virus
type-1 Tat is an integral component of the activated transcription-elongation
complex. Proc. Natl. Acad. Sci. USA 93:2505–2510.
30. Kerppola, T. K., and C. M. Kane. 1990. Analysis of signals for transcription
termination by purified RNA polymerase II. Biochemistry 29:269–278.
31. Kim, J. B., and P. A. Sharp. 2001. Positive transcription elongation factor b
phosphorylates hSPT5 and RNA polymerase II carboxyl-terminal domain
independently of cyclin-dependent kinase-activating kinase. J. Biol. Chem.
276:12317–12323.
32. Kulish, D., and K. Struhl. 2001. TFIIS enhances transcriptional elongation
through an artificial arrest site in vivo. Mol. Cell. Biol. 21:4162–4168.
33. Kumar, K. P., S. Akoulitchev, and D. Reinberg. 1998. Promoter-proximal
stalling results from the inability to recruit transcription factor IIH to the
transcription complex and is a regulated event. Proc. Natl. Acad. Sci. USA
95:9767–9772.
34. Kwak, Y. T., D. Ivanov, J. Guo, E. Nee, and R. B. Gaynor. 1999. Role of the
human and murine cyclin T proteins in regulating HIV-1 Tat-activation. J.
Mol. Biol. 288:57–69.
35. Laspia, M. F., A. P. Rice, and M. B. Mathews. 1989. HIV-1 Tat protein
increases transcriptional initiation and stabilizes elongation. Cell 59:283–292.
36. Lin, R., D. Gewert, and J. Hiscott. 1999. Differential transcriptional activa-
tion in vitro by NF-
B/Rel proteins. J. Biol. Chem. 270:3123–3131.
37. Liu, Y., C. Suñé, and M. A. Garcia-Blanco. 1999. Human immunodeficiency
virus type 1 Tat-dependent activation of an arrested RNA polymerase II
elongation complex. Virology 255:337–346.
38. Mancebo, H. S. Y., G. Lee, J. Flygare, J. Tomassini, P. Luu, Y. Zhu, J. Peng,
C. Blau, D. Hazuda, D. Price, and O. Flores. 1997. p-TEFb kinase is required
for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev.
11:2633–2644.
39. Marciniak, R. A., B. J. Calnan, A. D. Frankel, and P. A. Sharp. 1990. HIV-1
Tat protein trans-activates transcription in vitro. Cell 63:791–802.
40. Marciniak, R. A., and P. A. Sharp. 1991. HIV-1 Tat protein promotes
1092 BOURGEOIS ET AL. MOL. CELL. BIOL.
 o
n








formation of more-processive elongation complexes. EMBO J. 10:4189–
4196.
41. Palangat, M., and R. Landick. 2001. Roles of RNA:DNA hybrid stability,
RNA structure, and active site conformation in pausing by human RNA
polymerase II. J. Mol. Biol. 311:265–282.
42. Palangat, M., T. I. Meier, R. G. Keene, and R. Landick. 1998. Transcrip-
tional pausing at 62 of the HIV-1 nascent RNA modulates formation of the
TAR RNA structure. Mol. Cell 1:1033–1042.
43. Parada, C. A., and R. G. Roeder. 1996. Enhanced processivity of RNA
polymerase II triggered by Tat-induced phosphorylation of its carboxy-ter-
minal domain. Nature 384:375–378.
44. Parada, C. A., J.-B. Yoon, and R. G. Roeder. 1995. A novel LBP-1-mediated
restriction of HIV-1 transcription at the level of elongation in vitro. J. Biol.
Chem. 270:2274–2283.
45. Pasman, Z., and P. H. von Hippel. 2000. Regulation of Rho-dependent
transcription termination by NusG is specific to the Escherichia coli elonga-
tion complex. Biochemistry 39:5573–5585.
46. Ping, Y.-H., and T. M. Rana. 1999. Tat-associated kinase (P-TEF-b): a
component of transcription preinitiation and elongation complexes. J. Biol.
Chem. 274:7399–7404.
47. Ping, Y. H., and T. M. Rana. 2001. DSIF and NELF interact with RNA
polymerase II elongation complex and HIV-1 Tat stimulates pTEFb-medi-
ated phosphorylation of RNA polymerase II and DSIF during transcription
elongation. J. Biol. Chem. 276:12951–12958.
48. Price, D. H. 2000. P-TEFb, a cyclin-dependent kinase controlling elongation
by RNA polymerase II. Mol. Cell. Biol. 20:2629–2634.
49. Renner, D. B., Y. Yamaguchi, T. Wada, H. Handa, and D. H. Price. 2001. A
highly purified RNA polymerase II elongation control system. J. Biol. Chem.
276:42601–42609.
50. Rittner, K., M. J. Churcher, M. J. Gait, and J. Karn. 1995. The human
immunodeficiency virus long terminal repeat includes a specialised initiator
element which is required for Tat-responsive transcription. J. Mol. Biol.
248:562–580.
51. Selby, M. J., E. S. Bain, P. Luciw, and B. M. Peterlin. 1989. Structure,
sequence and position of the stem-loop in TAR determine transcriptional
elongation by Tat through the HIV-1 long terminal repeat. Genes Dev.
3:547–558.
52. Sodroski, J., R. Patarca, C. Rosen, F. Wong-Staal, and W. A. Haseltine.
1985. Location of the trans-acting region on the genome of human T-cell
lymphotropic virus type III. Science 229:74–77.
53. Suñé, C., and M. A. Garcia-Blanco. 1995. Transcriptional trans-activation by
human immunodeficiency virus type 1 Tat requires specific coactivators that
are not basal factors. J. Virol. 69:3098–3107.
54. Taube, R., K. Fujinaga, J. Wimmer, M. Barboric, and B. M. Peterlin. 1999.
Tat transactivation: a model for the regulation of eukaryotic transcriptional
elongation. Virology 264:245–253.
55. Tirode, F., D. Busso, F. Coin, and J.-M. Egly. 1999. Reconstitution of the
transcription factor TFIIH: assignment of functions for the three subunits
XPB, XPD, and cdk7. Mol. Cell 3:87–95.
56. von Hippel, P. H. 1998. An integrated model of the transcription complex in
elongation, termination and editing. Science 281:660–665.
57. Wada, T., G. Orphanides, J. Hasegawa, D.-K. Kim, D. Shima, Y. Yamaguchi,
A. Fukada, K. Hisatake, O. Sangtaek, D. Reinberg, and H. Handa. 2000.
FACT relieves DSIF/NELF-mediated inhibition of transcriptional elonga-
tion and reveals functional differences between p-TEFb and TFIIH. Mol.
Cell 5:1067–1072.
58. Wada, T., T. Takagai, Y. Yamaguchi, D. Watanabe, and H. Handa. 1998.
Evidence that pTEFb alleviates the negative effect of DSIF on RNA poly-
merase II-dependent transcription in vitro. EMBO J. 17:7395–7403.
59. Wada, T., T. Takagi, Y. Yamaguchi, A. Ferdous, T. Imai, S. Hirose, S.
Sugimoto, K. Yano, G. A. Hartzog, F. Winston, S. Buratowski, and H.
Handa. 1998. DSIF, a novel transcription elongation factor that regulates
RNA polymerase II processivity, is composed of human Spt4 and Spt5
homologs. Genes Dev. 12:343–356.
60. Wei, P., M. E. Garber, S.-M. Fang, W. H. Fischer, and K. A. Jones. 1998. A
novel cdk9-associated c-type cyclin interacts directly with HIV-1 Tat and
mediates its high-affinity, loop specific binding to TAR RNA. Cell 92:451–
462.
61. Wu-Baer, F., W. S. Lane, and R. B. Gaynor. 1998. Role of the human
homolog of the yeast transcription factor SPT5 in HIV-1 Tat-activation. J.
Mol. Biol. 277:179–197.
62. Yamaguchi, Y., T. Takagi, T. Wada, K. Yano, A. Furuya, S. Sugimoto, J.
Hasegawa, and H. Handa. 1999. NELF, a multisubunit complex containing
RD, cooperates with DSIF to repress RNA polymerase II elongation. Cell
97:41–51.
63. Yamaguchi, Y., T. Wada, D. Watanabe, T. Takagi, J. Hasegawa, and H.
Handa. 1999. Structure and function of the human transcription elongation
factor DSIF. J. Biol. Chem. 274:8085–8092.
64. Zawel, L., P. Kumar, and D. Reinberg. 1995. Recycling of the general
transcription factors during RNA polymerase II transcription. Genes Dev.
9:1479–1490.
65. Zhou, M., M. A. Halanski, M. F. Radonovich, F. Kashanchi, J. Peng, D. H.
Price, and J. N. Brady. 2000. Tat modifies the activity of CDK9 to phos-
phorylate serine 5 of the RNA polymerase II carboxyl-terminal domain
during human immunodeficiency virus type 1 transcription. Mol. Cell. Biol.
20:5077–5086.
66. Zhou, Q., D. Chen, E. Pierstorff, and K. Luo. 1998. Transcription elongation
factor p-TEFb mediates Tat activation of HIV-1 transcription at multiple
stages. EMBO J. 17:3681–3691.
67. Zhou, Q., and P. A. Sharp. 1995. Novel mechanism and factor for regulation
by HIV-1 Tat. EMBO J. 14:321–328.
68. Zhou, Q., and P. A. Sharp. 1996. Tat-SF1: cofactor for stimulation of tran-
scriptional elongation by HIV-1 Tat. Science 274:605–610.
69. Zhu, Y., T. Pe’ery, J. Peng, Y. Ramanathan, N. Marshall, T. Marshall, B.
Amendt, M. B. Mathews, and D. H. Price. 1997. Transcription elongation
factor p-TEFb is required for HIV-1 Tat trans-activation in vitro. Genes Dev.
11:2622–2632.
VOL. 22, 2002 SPT-5 PREVENTS PREMATURE RNA RELEASE 1093
 o
n
 June 19, 2014 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
